“Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children.
Of the 25 subjects in the trial, 13 were being treated with clobazam (CLB). Because CLB and CBD are both metabolized in the cytochrome P450 (CYP) pathway, we predicted a drug-drug interaction, which we evaluate in this article…
Monitoring of CLB and nCLB levels is necessary for clinical care of patients concomitantly on CLB and CBD.
Nonetheless, CBD is a safe and effective treatment of refractory epilepsy in patients receiving CLB treatment.”